Skip to content

Study · Randomized controlled trial · n = 250 · 1992

4 results

Phase III randomised study of zoladex versus stilboestrol in the treatment of advanced prostate cancer.

Waymont B, Lynch TH, Dunn JA, Emtage LA, Arkell DG, Wallace DM, Blackledge GR

British journal of urology1 Jun 1992Cited by 22 (Europe PMC)

PMID1386272 (opens in a new tab)DOI10.1111/j.1464-410x.1992.tb15633.x (opens in a new tab)PepBankPUB-01386272
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In advanced or metastatic prostate cancer, goserelin achieved the first response earlier than stilboestrol.

    In plain wordsIn advanced or metastatic prostate cancer, the first response occurred earlier with goserelin than stilboestrol.

    Peptide
    Goserelin
    Outcome
    DecreaseTime to first response
    Study

    n = 250

    Comparator
    Stilboestrol
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the Zoladex arm the time to first response was achieved earlier and more patients reported an improvement in symptoms.
    2 context sentences
    Summary · context
    An open randomised Phase III trial was conducted of the depot GnRH analogue goserelin (Zoladex) versus stilboestrol (3 mg/day) in patients with advanced or metastatic prostate cancer.
    Summary · context
    The study included 250 patients and the median follow-up was 43 months.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In advanced or metastatic prostate cancer, more patients reported symptom improvement with goserelin than stilboestrol.

    In plain wordsIn advanced or metastatic prostate cancer, more patients reported improved symptoms with goserelin than stilboestrol.

    Peptide
    Goserelin
    Outcome
    IncreaseSymptom improvement
    Study

    n = 250

    Comparator
    Stilboestrol
    Outcome group
    Cancer Symptoms · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the Zoladex arm the time to first response was achieved earlier and more patients reported an improvement in symptoms.
    2 context sentences
    Summary · context
    An open randomised Phase III trial was conducted of the depot GnRH analogue goserelin (Zoladex) versus stilboestrol (3 mg/day) in patients with advanced or metastatic prostate cancer.
    Summary · context
    The study included 250 patients and the median follow-up was 43 months.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In advanced or metastatic prostate cancer, survival did not significantly differ between goserelin and stilboestrol.

    In plain wordsIn advanced or metastatic prostate cancer, survival did not significantly differ between goserelin and stilboestrol.

    Peptide
    Goserelin
    Outcome
    No significant changeSurvival
    Study

    n = 250

    Comparator
    Stilboestrol
    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was no statistically significant difference between the Zoladex and the stilboestrol arms with regard to survival and time to treatment failure.
    2 context sentences
    Summary · context
    An open randomised Phase III trial was conducted of the depot GnRH analogue goserelin (Zoladex) versus stilboestrol (3 mg/day) in patients with advanced or metastatic prostate cancer.
    Summary · context
    The study included 250 patients and the median follow-up was 43 months.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In advanced or metastatic prostate cancer, time to treatment failure did not significantly differ between goserelin and stilboestrol.

    In plain wordsIn advanced or metastatic prostate cancer, time to treatment failure did not significantly differ between goserelin and stilboestrol.

    Peptide
    Goserelin
    Outcome
    No significant changeTime to treatment failure
    Study

    n = 250

    Comparator
    Stilboestrol
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was no statistically significant difference between the Zoladex and the stilboestrol arms with regard to survival and time to treatment failure.
    2 context sentences
    Summary · context
    An open randomised Phase III trial was conducted of the depot GnRH analogue goserelin (Zoladex) versus stilboestrol (3 mg/day) in patients with advanced or metastatic prostate cancer.
    Summary · context
    The study included 250 patients and the median follow-up was 43 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.